SCHEMBL22022933

SCHEMBL22022933

O=C(Cc1ccc(-c2ccc(CO)cc2)cc1)Nc1cc(Cl)ccc1C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
ACLY P53396 1/20 0.62
KDM4E B2RXH2 3/20 0.59
ALDH1A1 P00352 3/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
KDM5A P29375 1/20 0.55
KDM4C Q9H3R0 1/20 0.55
KDM5B Q9UGL1 1/20 0.55
GRIK1 P39086 6/20 0.53
DNM2 P50570 1/20 0.51
TRPM4 Q8TD43 2/20 0.49
HCAR2 Q8TDS4 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22022864 0.91 ACLY (0.75) MEN1KMT2AACLYKDM4EALDH1A1
SCHEMBL22022929 0.91 ACLY (0.65) MEN1KMT2AACLYKDM4EALDH1A1
SCHEMBL22022868 0.90 KMT2A (0.68) MEN1KMT2AACLYKDM4EALDH1A1
SCHEMBL1309256 0.89 MEN1 (0.78) MEN1KMT2AACLYKDM4EALDH1A1
SCHEMBL22022916 0.89 MEN1 (0.70) MEN1KMT2AACLYKDM4EALDH1A1
SCHEMBL22022862 0.88 HCAR2 (0.65) MEN1KMT2AACLYKDM4EALDH1A1
SCHEMBL22022867 0.85 MEN1 (0.66) MEN1KMT2AACLYKDM4EALDH1A1
SCHEMBL1308597 0.85 MEN1 (0.72) MEN1KMT2AACLYKDM4EALDH1A1
SCHEMBL22022869 0.84 MEN1 (0.61) MEN1KMT2AACLYKDM4EALDH1A1
SCHEMBL22022893 0.84 MEN1 (0.65) MEN1KMT2AACLYKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2022-02-24 US disclosed
EP-3890734-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2021-10-13 EP disclosed
WO-2020115019-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2020-06-11 WO disclosed
EP-3662908-A1 MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-06-10 EP disclosed
EP-3662908-A1 MODULATING COMPOUNDS OF KCHIP2 AND ITS USE FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220054438-A1 KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES KCNK2, KCNT2, KCNT1 MEN1 4366/4885KMT2A 1216/4885ACLY 3559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.